| Mechanism | Drug | Disease or Use |
|---|
| Reversible, somewhat COX-2 selective inhibitor | |
| Softener of formed stools by attracting fat and water to the stool (essentially “grease”) | |
| Humanized chimeric monoclonal antibody against TNF-α | |
| Non-absorbable sugars | |
| Reduced breakdown of proteoglycans, protease inhibition, inhibition of prostaglandin synthesis | |
| Anti-inflammatory glucocorticoid receptor agonists, immunosuppressants | |
| Muscarinic receptor antagonist, intended to reduce influence of the vestibular system on the chemoreceptor trigger zone | |
| 5-HT3 receptor antagonist, intended to block serotonin activation of the vagus nerve and the chemoreceptor trigger zone | |
| Kill Helicobacter pylori (Quadruple/backup therapy. Name a drug other than a PPI) | |
| Non-absorbable salt | |
| Kill Helicobacter pylori (First line therapy. Name a drug other than a PPI) | |
| Neutralize stomach acid | |
| ClC-2 channel activator, intended to increase chloride secretion into the intestinal lumen | |
| Hygroscopic indigestible fiber (absorb water in intestinal lumen or draw water into the intestinal lumen, increase bulk- can either liquefy or soldify stool) | |
| SERM, same actions as estrogen | |
| TNF-α receptor fused to Fc region | |
| Inhibits microtubule assembly, intended to block replication of inflammatory cells | |
| Calcineurin inhibitor, immunosuppressant | |
| Irreversible, non-selective inhibitor of cyclooxygenases | |
| Irreversible proton pump (H+/K+-ATPase) inhibitors, block secretion of gastric acid | |
| Recombinant IL-1 receptor antagonist | |
| Reversible, non-selective inhibitors of cyclooxygenases | |
| Osteoporosis treatment | |
| Binds bile salts and some bacterial toxins | |
| Inhibitor of cyclooxygenase and 5-lipoxygenase in GI tract, modulator of B-cell responses and angiogenesis (sulfasalazine metabolized to mesalamine by colon bacteria) | |
| Pyrimidine synthesis inhibitor | |
| Synthetic calcitonin analog, inhibition of osteoclast action | |
| Pyrophosphate analogs, inhibition of osteoclast action, induce osteoclast apoptosis | |
| | Mechanism | Drug | Disease or Use |
|---|
| Reversible, relatively-selective COX-2 inhibitor | |
| Purine synthesis inhibitor, immunosuppressant | |
| Reversible, non-selective inhibitor of cyclooxygenase, inhibitor of urate reabsorption in the kidney | |
| D2 receptor antagonists (metoclopramide also a muscarinic receptor agonist), intended to block dopamine activation of the chemoreceptor trigger zone and vomiting center | |
| Promote peristalsis | |
| Fully human monoclonal antibody against RANKL (the primary signal to promote maturation of pre-osteoclasts to osteoclasts) | |
| Peripheral µ receptor agonist (slows GI motility) | |
| Immunoglobulin fusion protein that binds to antigen-presenting cells and blocks costimulatory signals required for T-cell activation | |
| Inhibition of osteoclast action, induces osteoclast apoptosis | |
| Viscous gel at acidic pH, intended to protect the mucosa from gastric acid and pepsin by creating a physical barrier | |
| Weak µ receptor agonists | |
| Inhibitor of dihydrofolate reductase, inducer of adenosine release | |
| Glucocorticoid receptor agonist (several mechanisms) | |
| Inhibitors of urate reabsorption in the kidney | |
| NK1 receptor antagonist, intended to block substance P activation of the vagus nerve and chemoreceptor trigger zone | |
| Weak, reversible, non-selective inhibitor of cyclooxygenases mainly in CNS | |
| Kill H. pylori and other bacteria, inhibit prostaglandin-mediated inflammation and intestinal hypermotility, inhibit intestinal secretion | |
| Non-absorbable salts | |
| Fully human monoclonal antibody against TNF-α | |
| H1 receptor + muscarinic receptor antagonists, intended to reduce influence of the vestibular system on the chemoreceptor trigger zone | |
| H2 receptor antagonists, remove histamine control of gastric acid secretion | |
| Parathyroid hormone agonist, stimulation of osteoblast action more than osteoclast action (with intermittent injection), increases GI calcium absorption, increases renal tubular ca | |
| PGE2 receptor agonist (PGE1 analog), intended to replace prostaglandin eliminated by NSAID use | |
| Modulator of cytokine secretion, inhibitor of lysosomal enzyme release, inhibitor of macrophage function | |
| Kill Helicobacter pylori (First line therapy for penicillin allergy. Name the drug substituted for amoxicillin) | |
| Reversible, non-selective inhibitors of cyclooxygenases | |
| Inhibitors of xanthine oxidase, intended to reduce uric acid synthesis | |
|
Typing Challenge
Drawing a Blank
Drawing a Blank II
